Cyclacel Pharmaceuticals (NASDAQ:BGMS) Announces Quarterly Earnings Results

Cyclacel Pharmaceuticals (NASDAQ:BGMS) posted its quarterly earnings results on Monday. The company reported ($2.21) earnings per share for the quarter, Zacks reports. The firm had revenue of $0.67 million for the quarter.

Cyclacel Pharmaceuticals Stock Performance

BGMS traded down $0.03 on Tuesday, hitting $0.94. The company had a trading volume of 25,906 shares, compared to its average volume of 89,036. The stock’s fifty day simple moving average is $1.04. Cyclacel Pharmaceuticals has a 1 year low of $0.73 and a 1 year high of $100.75. The stock has a market cap of $4.59 million, a price-to-earnings ratio of -0.01 and a beta of -0.45.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cyclacel Pharmaceuticals in a research report on Friday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies that target the cell cycle and related regulatory pathways for the treatment of cancer and other proliferative diseases. The company’s research and development efforts center on kinase and cell-cycle inhibitors designed to disrupt tumor growth and induce cancer cell death. Cyclacel advances programs through preclinical development and clinical trials with the aim of delivering new therapeutic options for patients with solid tumors and hematologic malignancies.

Key activities at Cyclacel include in-house drug discovery, translational research, and the clinical development of lead candidate molecules.